WiOptix, Inc.

Every year in the US, about 1.3M biopsies are performed based on a preliminary cancer determi­nation. About 1M of these biopsies will require open surgery under anesthesia. Only about 15% of the surgeries will result in a cancer diagnosis – alternatively 85% of these biopsies will be unnec­essary if the physicians would have been able to accurately identify cancer during the preliminary examination. In addition, nearly 20M breast biopsies are preformed world-wide each year with about the same proportion of negative results.

WOI’s approach is to enter the optical imaging market with a system used in conjunction with existing endoscopic products. WOI probes and software extend the existing capabilities of en­doscopes to encompass cellular level observation. WOI systems will utilize endoscopes’ biopsy channels without any modifications, allowing for a smooth transition to an expanded diagnostic capability.

Our platform systems can be sold to more than 20,000 hospitals and clinics that have cancer treat­ment and diagnostic facilities. Meanwhile WOI probes will be affordable for one-time use. WOI product platform is anticipated to extend into the area of vascu­lar imaging and surgery as well as in the veterinary medicine market.